Skip to main content

Table 3 Methylation patterns of the PTPRO genes in primary tumors, plasma samples from 24 breast cancer patients with Clinicopathological parameters

From: PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy

Patient NO.

Tumor

Plasma

HER2

ER

PR

Age

Grade

pT

pN

pM

1

ā—

ā—

+

-

-

52

2

2

1

0

2

ā—

ā—

+

-

-

49

2

2

0

0

3

ā—

ā—

+

-

-

41

2

3

1

0

4

ā—

ā—

-

-

-

41

3

2

0

0

5

ā—

ā—

-

+

+

89

3

4

x

0

6

ā—

ā—

-

+

-

58

3

4

2

0

7

ā—

ā—

-

+

-

57

2

4

2

0

8

ā—

ā—

-

+

-

57

1

2

0

0

9

ā—

ā—

-

+

-

54

2

2

0

0

10

ā—

ā—

-

+

+

30

3

3

3

0

11

ā—

ā—

-

-

-

48

1

4

2

0

12

ā—

ā—‹

+

+

+

42

3

4

2

0

13

ā—

ā—‹

+

-

-

52

2

2

0

0

14

ā—

ā—‹

+

+

+

45

2

4

2

0

15

ā—

ā—‹

-

+

+

57

2

2

1

0

16

ā—

ā—‹

-

+

-

62

2

2

2

0

17

ā—

ā—‹

-

+

+

46

2

4

3

0

18

ā—

ā—‹

-

+

+

60

3

2

2

0

19

ā—‹

ā—‹

+

+

-

42

1

2

1

0

20

ā—‹

ā—‹

+

-

-

61

3

3

0

0

21

ā—‹

ā—‹

-

+

-

36

2

3

3

0

22

ā—‹

ā—‹

-

+

+

50

1

1

0

0

23

ā—‹

ā—‹

-

+

-

54

3

3

0

0

24

ā—‹

ā—‹

-

+

-

54

2

1

0

0

Methylation ratio (%)

18/24 (75.0)

11/24 (45.8)

        
  1. ā—, Methylated; ā—‹, unmethylated.